Scotiabank has recently initiated Vertex Pharmaceuticals Incorporated (VRTX) stock to Sector Perform rating, as announced on October 16, 2024, according to Finviz. Earlier, on October 10, 2024, Raymond James had resumed the stock to Mkt Perform. Barclays also reduced Equal Weight rating with a price target of $509. Additionally, Redburn Atlantic initiated Buy rating on June 27, 2024, with a target price of $545. Evercore ISI analysts, in their report published on April 11, 2024, also raised rating for Vertex Pharmaceuticals Incorporated’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Vertex Pharmaceuticals Incorporated (VRTX) Stock Trading Recap
On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock opened at $474.47 and touched a low of $464.78 during the day, reaching a high of $477.47. The volume of shares traded was 0.99 million falling short of the average volume of 1.09 million.
Sponsored
VRTX Stock Performance and Moving Averages
In recent trading, Vertex Pharmaceuticals Incorporated (VRTX) stock price has shown some volatility, fluctuating -3.53% over the last five trades and 1.52% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 17.29%, and it has plunged by -4.51% in the previous three months. Currently, VRTX is trading at -0.27%, -1.07%, and 4.64% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, VRTX, a Healthcare sector stock, is trading -7.95% below its 52-week high but remains 37.48% above its 52-week low. The Average True Range (ATR) (14 days) of 10 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Vertex Pharmaceuticals Incorporated’s Profitability and Valuation Ratios
Vertex Pharmaceuticals Incorporated’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -3.79% and a profit margin of -4.75%, with a gross margin of 17.29%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Vertex Pharmaceuticals Incorporated’s market capitalization stands at $121.32 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The forward P/E ratio, which uses projected earnings for the next financial year, is 25.14. Additionally, the Price-to-Sales Ratio is 11.75, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 8.21, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.26% of Vertex Pharmaceuticals Incorporated (VRTX)’s shares, while financial institutions hold 92.52%.
Notable insider trades include Biller Jonathan, EVP and Chief Legal Officer at Vertex Pharmaceuticals Incorporated (VRTX), who sold 999 shares on Oct 02 ’24, at $461.66 each, totaling $0.46 million. On Aug 30 ’24, LEIDEN JEFFREY M, Executive Chairman, sold 3784 shares for $499 each, amounting to $1.89 million. Additionally, on Aug 30 ’24, Bhatia Sangeeta N. sold 646 shares at $500 each, generating $0.32 million.
